# A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

> **NCT05952869** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 303 (actual)

## Conditions studied

- Hypercholesterolemia
- Familial Hypercholesterolemia

## Interventions

- **DRUG:** Enlicitide Decanoate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05952869
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-08
- **Primary completion:** 2025-04-07
- **Final completion:** 2025-04-07
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05952869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05952869, "A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05952869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*